Clinical presentations of hypertrophic cardiomyopathy and implications for therapy

Authors

  • Carles Díez-López Advanced Heart Failure and Heart Transplant Unit. Heart Institute. Bellvitge University Hospital. Barcelona, Spain
  • Joel Salazar-Mendiguchía Health in Code. Cardiovascular Genetics Department. A Coruña, Spain and Genetics Department. Universitat Autònoma de Barcelona, Spain

DOI:

https://doi.org/10.21542/gcsp.2018.19

Abstract

[first paragraph of article]

Hypertrophic cardiomyopathy (HCM) is diagnosed in the presence of left ventricular hypertrophy of ≥15 mm in adult index cases, or ≥13 mm in relatives of known affected patients, that is not solely explained by abnormal loading conditions. In children, the left ventricle (LV) wall thickness should be more than two standard deviations above the predicted population mean. The typical anatomo-pathological findings include myocyte hypertrophy, disarray, interstitial fibrosis and small-vessel disease. Although all the myocytes are supposed to be affected, pathological alterations are not uniformly distributed throughout the myocardium. Asymmetrical hypertrophy of the interventricular septum is the most commonly observed phenotype, but any pattern of hypertrophy is consistent with the diagnosis.

Downloads

Published

2018-10-24

Issue

Section

Review articles